Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme.

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Georg Karpel-MasslerMarc-Eric Halatsch

Abstract

The epidermal growth factor receptor (HER1/EGFR) is known to be disregulated in a large subgroup of glioblastoma multiforme cases. Disregulation of HER1/EGFR is related to malignant transformation and tumor growth in various human cancers, including malignant glioma. One mechanism that may lead to disregulated HER1/EGFR signaling is the intrinsic alteration of the receptor structure due to mutational changes. The most common mutant form of HER1/EGFR, named variant III (EGFRvIII), results from an 801 bp in-frame deletion in the DNA sequence encoding the extracellular ligand-binding domain. Independent of ligand-binding, EGFRvIII is constitutively activated and beyond external control. Since its cellular expression was shown to relate enhanced tumorigenicity, various therapeutic strategies were developed to target EGFRvIII, including monoclonal antibodies, vaccination therapies and small-molecule tyrosine kinase inhibitors. In this review, we focus on ribozyme-mediated inhibition of EGFRvIII messenger RNA expression as a gene therapeutic approach for EGFRvIII-expressing glioblastoma multiforme.

References

Aug 14, 1992·Biochemical and Biophysical Research Communications·N YuyamaK Taira
Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·A J WongB Vogelstein
Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N SugawaV P Collins
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·P A HantzopoulosE Gilboa
May 12, 1986·Nucleic Acids Research·C J HutchinsR H Symons
Aug 2, 1994·Proceedings of the National Academy of Sciences of the United States of America·R NishikawaH J Huang
Jan 1, 1993·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D M Long, O C Uhlenbeck
Jul 12, 2002·Nature·Jennifer A Doudna, Thomas R Cech
Mar 18, 2003·International Journal of Cancer. Journal International Du Cancer·Xunyi LuoCareen K Tang
Jul 9, 2009·Molecular Cancer Research : MCR·Georg Karpel-MasslerMarc-Eric Halatsch
Sep 1, 2009·Cellular and Molecular Life Sciences : CMLS·Cedric ReymondJean-Pierre Perreault

❮ Previous
Next ❯

Citations

Dec 20, 2011·British Journal of Neurosurgery·Gina Farias-EisnerE Sander Connolly
Oct 1, 2019·Current Gene Therapy·Ling-Yan ZhouTing Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.